Ditter H, Müller K D, Bahavar H, Schlepper M
Abt. Kardiologie, Kerckhoff-Klinik, Bad Nauheim.
Z Kardiol. 1991 Feb;80(2):167-70.
Ten patients suffering from an angiographically documented coronary two- or three-vessel disease were examined to evaluate the effects of the specific bradycardiac agent alinidine during a bicycle stress test. Hemodynamic and electrocardiographic parameters were compared before and after an intravenous application of 30 mg of the substance. The alinidine plasma levels 30 min after the injection were 160.6 +/- 22.5 ng/ml) (mean +/- SEM). Alinidine significantly (p less than 0.05) reduced the resting levels of heart rate (8.5%), double product (10.3%), myocardial oxygen consumption (9.1%), and cardiac output (9.0%). During exercise, significantly less ST-segment depression (p less than 0.001) in the EKG was observed after alinidine application in nine out of 10 patients, and the rise of pulmonary artery pressure was significantly reduced (34.7 vs 38.1 mm Hg, mean p less than 0.05). However, alinidine had no effect on the maximum heart rate at the end of exercise. We, therefore, assume that the substance has additional anti-ischemic properties.
对10例经血管造影证实患有冠状动脉双支或三支血管病变的患者进行了检查,以评估特异性心动过缓药物阿利尼定在自行车运动负荷试验中的作用。在静脉注射30mg该药物前后,对血流动力学和心电图参数进行了比较。注射后30分钟阿利尼定的血浆水平为160.6±22.5ng/ml(平均值±标准误)。阿利尼定显著(p<0.05)降低了静息心率水平(8.5%)、双乘积(10.3%)、心肌耗氧量(9.1%)和心输出量(9.0%)。在运动期间,10例患者中有9例在应用阿利尼定后,心电图中ST段压低显著减少(p<0.001),肺动脉压升高也显著降低(34.7对38.1mmHg,平均p<0.05)。然而,阿利尼定对运动结束时的最大心率没有影响。因此,我们认为该物质具有额外的抗缺血特性。